September 28, 2017 / 8:09 PM / a year ago

BRIEF-U.S. FDA takes steps to stem opioid misuse and abuse

Sept 28 (Reuters) - U.S. Food and Drug Administration Commissioner Scott Gottlieb:

* U.S. FDA’s Commissioner Gottlieb says this week, issued letters notifying 74 manufacturers of IR opioid analgesics intended for use in outpatient setting‍​

* FDA’s Gottlieb-the letters notified the manufacturers their drugs will be subject to more stringent criteria under a Risk Evaluation, Mitigation Strategy‍​

* ‍FDA’s Gottlieb says the Risk Evaluation and Mitigation Strategy requires that training be made available to health care providers who prescribe IR opioids​

* ‍FDA's Gottlieb-will soon issue guidance for potential applicants who plan to seek approval of generic version of abuse-deterrent formulations of opioid drugs Source text: (

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below